FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials

FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

Aug 1, 2024 - 04:00
FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials
FibroGen’s pamrevlumab failed to prove its efficacy in two Phase III trials prompting the company to initiate cost-saving measures.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow